AVXL (Anavex Life Sciences) Total Equity: $126.62 Mil (As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.53
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Total Equity?

Anavex Life Sciences AVXL -3.25% 30 Total Equity is $126.62 Mil as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's total equity for the quarter that ended in Dec. 2025 was $126.62 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Anavex Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Total Equity Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.82 142.49 141.85 120.26 94.87

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.92 99.76 90.96 94.87 126.62
AVXL
30GF Score
Anavex Life Sciences Corp AVXL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Anavex Life Sciences's Total Equity for the fiscal year that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=103.815-8.946
=94.87

Anavex Life Sciences's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=132.989-6.371
=126.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $126.62 Mil mean?
Anavex Life Sciences (AVXL) has a Total Equity of $126.62 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' Total Equity too high?
Anavex Life Sciences' current Total Equity is $126.62 Mil. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Total Equity compare to SLGL and FATE?
Anavex Life Sciences' Total Equity of $126.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Anavex Life Sciences and its competitors. Anavex Life Sciences's current Total Equity is $126.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Total Equity of $126.62 Mil. The current Total Equity is $126.62 Mil. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Total Equity is $126.62 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.53
Price